Epigenetic mechanisms of breast cancer: An update of the current knowledge

Epigenomics

Volumn 6, Issue 6, 2014, Pages 651-664

  Karsli Ceppioglu, Seher ^a,b,c   Dagdemir, Aslihan ^a,b   Judes, Gaëlle ^a,b   Ngollo, Marjolaine ^a,b   Penault Llorca, Frédérique ^a,b   Pajon, Amaury ^a,b   Bignon, Yves Jean ^a,b   Bernard Gallon, Dominique ^a,b  

^a CENTRE JEAN PERRIN   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c MARMARA UNIVERSITY   (Turkey)

Author keywords

BRCA1; breast cancer; DNA methylation; epigenetic therapy; epigenetics; estrogen; EZH2; histone modification

Indexed keywords

3 DEAZANEPLANOCIN A; 4,4' ISOPROPYLIDENEDIPHENOL; 5 METHYLCYTOSINE; BEVACIZUMAB; BUTYRIC ACID; DIETHYLSTILBESTROL; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; KI 67 ANTIGEN; METHYL CPG BINDING PROTEIN; MICRORNA; PACLITAXEL; PANOBINOSTAT; POLYCOMB GROUP PROTEIN; PROGESTERONE; REPETITIVE DNA; ROMIDEPSIN; TAMOXIFEN; TRANSCRIPTION FACTOR EZH2; TRICHOSTATIN A; VORINOSTAT; ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASE INHIBITORS; HISTONES;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CHROMATIN STRUCTURE; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; DRUG MECHANISM; EPIGENETICS; EXON; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE MUTATION; GENETIC REGULATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; INVASIVE CARCINOMA; NONHUMAN; ONCOGENE; PROMOTER REGION; RADIOSENSITIZATION; REVIEW; TRANSPOSON; TUMOR INVASION; TUMOR SUPPRESSOR GENE; UPREGULATION; BREAST NEOPLASMS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETICS; HUMANS; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS;

EID: 84919787782     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.59     Document Type: Review

References (101)

1. Dworkin AM, Huang TH, Toland AE. Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment. Semin. Cancer Biol. 19(3), 165-171 (2009
2. Cortez CC, Jones PA. Chromatin, cancer and drug therapies. Mutat. Res. 647(1-2), 44-51 (2008
3. Khan SI, Aumsuwan P, Khan IA, Walker LA, Dasmahapatra AK. Epigenetic events associated with breast cancer and their prevention by dietary components targeting the epigenome. Chem. Res. Toxicol. 25(1), 61-73 (2012
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11-30 (2013
5. Dagdemir A, Durif J, Ngollo M, Bignon YJ, Bernard-Gallon D. Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines. Epigenomics 5(1), 51-63 (2013
6. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 61(8), 3225-3229 (2001
7. Suzuki J, Chen YY, Scott GK, et al. Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin. Cancer Res. 15(9), 3163-3171 (2009
8. Lo PK, Sukumar S. Epigenomics and breast cancer. Pharmacogenomics 9(12), 1879-1902 (2008
9. Veeck J, Esteller M. Breast cancer epigenetics: From DNA methylation to microRNAs. J. Mammary Gland Biol. Neoplasia 15(1), 5-17 (2010
10. Herceg Z, Vaissiere T. Epigenetic mechanisms and cancer: an interface between the environment and the genome. Epigenetics 6(7), 804-819 (2011
11. Okano M, Xie S, Li E. Dnmt2 is not required for de novo and maintenance methylation of viral DNA in embryonic stem cells. Nucleic Acids Res. 26(11), 2536-2540 (1998
12. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99(3), 247-257 (1999
13. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 16(1), 6-21 (2002
14. Wajed SA, Laird PW, Demeester TR. DNA methylation: an alternative pathway to cancer. Ann. Surg. 234(1), 10-20 (2001
15. Costa FF, Verbisck NV, Salim AC, et al. Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors. Oncogene 23(7), 1481-1488 (2004
16. Oshiro MM, Kim CJ, Wozniak RJ, et al. Epigenetic silencing of DSC3 is a common event in human breast cancer. Breast Cancer Res. 7(5), R669-680 (2005
17. Holm K, Hegardt C, Staaf J, et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 12(3), R36 (2010
18. Suzuki H, Toyota M, Carraway H, et al. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br. J. Cancer 98(6), 1147-1156 (2008
19. Veeck J, Niederacher D, An H, et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 25(24), 3479-3488 (2006
20. Veeck J, Noetzel E, Bektas N, et al. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer. Mol. Cancer 7, 83 (2008
21. Alvarez C, Tapia T, Cornejo V, et al. Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer. Mol. Carcinog. 52(6), 475-487 (2013
22. Kajabova V, Smolkova B, Zmetakova I, et al. RASSF1A promoter methylation levels positively correlate with estrogen receptor expression in breast cancer patients. Transl. Oncol. 6(3), 297-304 (2013
23. Li Y, Wei Q, Cao F, Cao X. Expression and promoter methylation of the RASSF1A gene in sporadic breast cancers in Chinese women. Oncol. Rep. 19(5), 1149-1153 (2008
24. Xu J, Shetty PB, Feng W, et al. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer 12, 243 (2012
25. Li L, Lee KM, Han W, et al. Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer. Hum. Mol. Genet. 19(21), 4273-4277 (2010
26. Fackler MJ, Umbricht CB, Williams D, et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res. 71(19), 6195-6207 (2011
27. Fang F, Turcan S, Rimner A, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci. Transl. Med. 3(75), 75ra25 (2011
28. Hill VK, Ricketts C, Bieche I, et al. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res. 71(8), 2988-2999 (2011
29. Guerrero-Preston R, Hadar T, Ostrow KL, et al. Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity. Oncol. Rep. 32(2), 505-512 (2014
30. Han LL, Hou L, Zhou MJ, et al. Aberrant NDRG1 methylation associated with its decreased expression and clinicopathological significance in breast cancer. J. Biomed. Sci. 20, 52 (2013
31. Ramos EA, Grochoski M, Braun-Prado K, et al. Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer. PLoS ONE 6(12), e29461 (2011
32. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev. 25(10), 1010-1022 (2011
33. Li Y, Li S, Chen J, et al. Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes. Hum. Mol. Genet. 23(20), 5378-5393 (2014
34. Lindqvist BM, Farkas SA, Wingren S, Nilsson TK. DNA methylation pattern of the SLC25A43 gene in breast cancer. Epigenetics 7(3), 300-306 (2012
35. Rao X, Evans J, Chae H, et al. CpG island shore methylation regulates caveolin-1 expression in breast cancer. Oncogene 32(38), 4519-4528 (2013
36. Dagdemir A, Durif J, Ngollo M, Bignon YJ, Bernard-Gallon D. Breast cancer: mechanisms involved in action of phytoestrogens and epigenetic changes. In Vivo 27(1), 1-9 (2013
37. Flanagan JM, Cocciardi S, Waddell N, et al. DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. Am. J. Hum. Genet. 86(3), 420-433 (2010
38. Ruike Y, Imanaka Y, Sato F, Shimizu K, Tsujimoto G. Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-Throughput sequencing. BMC Genomics 11, 137 (2010
39. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin. Cancer Res. 11(16), 5869-5877 (2005
40. Singh P, Yang M, Dai H, et al. Overexpression and hypomethylation of flap endonuclease 1 gene in breast and other cancers. Mol. Cancer. Res. 6(11), 1710-1717 (2008
41. Kim SJ, Kang HS, Chang HL, et al. Promoter hypomethylation of the N-Acetyltransferase 1 gene in breast cancer. Oncol. Rep. 19(3), 663-668 (2008
42. Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur. J. Pharmacol. 625(1-3), 131-142 (2009
43. Albert M, Helin K. Histone methyltransferases in cancer. Semin. Cell Dev. Biol. 21(2), 209-220 (2010
44. Hublitz P, Albert M, Peters AH. Mechanisms of transcriptional repression by histone lysine methylation. Int. J. Dev. Biol. 53(2-3), 335-354 (2009
45. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 6(11), 838-849 (2005
46. Elsheikh SE, Green AR, Rakha EA, et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 69(9), 3802-3809 (2009
47. Guendel I, Carpio L, Pedati C, et al. Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function. PLoS ONE 5(6), e11379 (2010
48. Choe MK, Hong CP, Park J, Seo SH, Roh TY. Functional elements demarcated by histone modifications in breast cancer cells. Biochem. Biophys. Res. Commun. 418(3), 475-482 (2012
49. Hong CP, Choe MK, Roh TY. Characterization of chromatin structure-Associated histone modifications in breast cancer cells. Genomics Inform. 10(3), 145-152 (2012
50. Hervouet E, Cartron PF, Jouvenot M, Delage-Mourroux R. Epigenetic regulation of estrogen signaling in breast cancer. Epigenetics 8(3), 237-245 (2013
51. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54(10), 2552-2555 (1994
52. Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol. Endocrinol. 19(7), 1740-1751 (2005
53. Ramos EA, Camargo AA, Braun K, et al. Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer. BMC Cancer 10, 23 (2010
54. Wei M, Grushko TA, Dignam J, et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 65(23), 10692-10699 (2005
55. Prabhu JS, Wahi K, Korlimarla A, et al. The epigenetic silencing of the estrogen receptor (ER) by hypermethylation of the ESR1 promoter is seen predominantly in triplenegative breast cancers in Indian women. Tumour Biol. 33(2), 315-323 (2012
56. Zhao L, Yu Z, Li Y, et al. Clinical implications of ERbeta methylation on sporadic breast cancers in Chinese women. Med. Oncol. 29(3), 1569-1575 (2012
57. Shen X, Liu Y, Hsu YJ, et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 32(4), 491-502 (2008
58. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100(20), 11606-11611 (2003
59. Ding L, Erdmann C, Chinnaiyan AM, Merajver SD, Kleer CG. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res. 66(8), 4095-4099 (2006
60. Doherty LF, Bromer JG, Zhou Y, Aldad TS, Taylor HS. In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: an epigenetic mechanism linking endocrine disruptors to breast cancer. Horm. Cancer 1(3), 146-155 (2010
61. Pal B, Bouras T, Shi W, et al Global changes in the mammary epigenome are induced by hormonal cues and coordinated by Ezh2. Cell Rep. 3(2), 411-426 (2013
62. Holm K, Grabau D, Lovgren K, et al. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol. Oncol. 6(5), 494-506 (2012
63. Ito K, Lim AC, Salto-Tellez M, et al. RUNX3 attenuates betacatenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14(3), 226-237 (2008
64. Fujii S, Ito K, Ito Y, Ochiai A. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J. Biol. Chem. 283(25), 17324-17332 (2008
65. Chi XZ, Yang JO, Lee KY, et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-Activated SMAD. Mol. Cell. Biol. 25(18), 8097-8107 (2005
66. Du J, Li L, Ou Z, et al. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells. Breast Cancer Res. Treat. 131(1), 65-73 (2012
67. Yoo KH, Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer. Int. J. Biol. Sci. 8(1), 59-65 (2012
68. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res. Treat. 91(2), 179-186 (2005
69. Dobrovic A, Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 57(16), 3347-3350 (1997
70. Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 21(9), 1761-1765 (2000
71. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl Cancer Inst. 92(7), 564-569 (2000
72. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26(14), 2126-2132 (2007
73. Stefansson OA, Jonasson JG, Olafsdottir K, et al. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics 6(5), 638-649 (2011
74. Wong EM, Southey MC, Fox SB, et al. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-Associated pathology in early-onset breast cancer. Cancer Prev. Res. 4(1), 23-33 (2011
75. Jung EJ, Kim IS, Lee EY, et al. Comparison of methylation profiling in cancerous and their corresponding normal tissues from korean patients with breast cancer. Ann. Lab. Med. 33(6), 431-440 (2013
76. Iwamoto T, Yamamoto N, Taguchi T, Tamaki Y, Noguchi S. BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation. Breast Cancer Res. Treat. 129(1), 69-77 (2011
77. Al-Moghrabi N, Al-Qasem AJ, Aboussekhra A. Methylationrelated mutations in the BRCA1 promoter in peripheral blood cells from cancer-free women. Int. J. Oncol. 39(1), 129-135 (2011
78. Sturgeon SR, Balasubramanian R, Schairer C, Muss HB, Ziegler RG, Arcaro KF. Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls. Epigenetics 7(11), 1258-1267 (2012
79. Bosviel R, Garcia S, Lavediaux G, et al. BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls. Cancer Epidemiol. 36(3), e177-e182 (2012
80. Bosviel R, Durif J, Guo J, et al. BRCA2 promoter hypermethylation in sporadic breast cancer. Omics 16(12), 707-710 (2012
81. Gonzalez ME, Duprie ML, Krueger H, et al. Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Cancer Res. 71(6), 2360-2370 (2011
82. Wang L, Huang H. EZH2 takes the stage when BRCA1 loses. Cell Cycle 12(23), 3575-3576 (2013
83. Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7, 47-60 (2013
84. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10), 1247-1252 (2007
85. Campas-Moya C. Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today 45(11), 787-795 (2009
86. Huang L, Pardee AB. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol. Med. 6(10), 849-866 (2000
87. Zhou Q, Shaw PG, Davidson NE. Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. Breast Cancer Res. Treat. 117(2), 443-451 (2009
88. Lauricella M, Ciraolo A, Carlisi D, Vento R, Tesoriere G. SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells. Biochimie 94(2), 287-299 (2012
89. Munster PN, Thurn KT, Thomas S, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br. J. Cancer 104(12), 1828-1835 (2011
90. Ramaswamy B, Fiskus W, Cohen B, et al. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res. Treat. 132(3), 1063-1072 (2012
91. Tate CR, Rhodes LV, Segar HC, et al. Targeting triplenegative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 14(3), R79 (2012
92. Nohara K, Yokoyama Y, Kano K. The important role of caspase-10 in sodium butyrate-induced apoptosis. Kobe J. Med. Sci. 53(5), 265-273 (2007
93. Cho HJ, Kim SY, Kim KH, et al. The combination effect of sodium butyrate and 5-Aza-2'-deoxycytidine on radiosensitivity in RKO colorectal cancer and MCF-7 breast cancer cell lines. World J. Surg. Oncol. 7, 49 (2009
94. Sharma D, Saxena NK, Davidson NE, Vertino PM. Restoration of tamoxifen sensitivity in estrogen receptornegative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 66(12), 6370-6378 (2006
95. Fan J, Yin WJ, Lu JS, et al. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J. Cancer Res. Clin. Oncol. 134(8), 883-890 (2008
96. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-Alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-Alpha-negative breast cancer cells. Cancer Res. 61(19), 7025-7029 (2001
97. Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM. Functional activation of the estrogen receptoralpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res. 71(5), 1893-1903 (2011
98. Chiang PK, Cantoni GL. Perturbation of biochemical transmethylations by 3-deazaadenosine in vivo. Biochem. Pharmacol. 28(12), 1897-1902 (1979
99. Liu S, Wolfe MS, Borchardt RT. Rational approaches to the design of antiviral agents based on S-Adenosyl-Lhomocysteine hydrolase as a molecular target. Antiviral Res. 19(3), 247-265 (1992
100. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21(9), 1050-1063 (2007
101. Toland AE. Aberrant epigenetic regulation in breast cancer (p91-122). In: Patho-Epigenetics of Disease. Minarovits J, Niller HH (Eds). Springer, NY, USA (2012